Table 1

Outcome assessments of the PAEPAD Study

Outcomes	Instruments/diagnostic criteria	Immediately post intervention	On discharge from OB ward	On disease flares	3 months postnatal	1 year postnatal	2 years postnatal
Primary outcomes
Cumulative incidence of AD at 2 years	Hanifin and Rajka						✕
Secondary outcomes
AD outcomes
Time to first AD episode	Hanifin and Rajka			✕
Time to first topical corticosteroid exposure				✕
Disease-related quality of life	IDQOL			✕
Disease severity	SCORAD, EASI and IGA			✕
Frequency of AD flares
AD disease-free days	IGA
Cumulative clinical visit duration	From the parents being seated within the consulting room to their exit thereafter			✕
Atopic march outcomes
Asthma incidence							✕
Recurrent wheeze incidence							✕
Rhinitis incidence							✕
Food sensitisation incidence	Allergen-specific IgE						✕
Obstetric outcomes
Mode of birth	Eutocic/dystocic/C-section		✕
Pathological pregnancy	Gestational diabetes, pre-eclampsia, placenta previa, placental abruption, prelabor rupture of membranes, puerperal infection, postpartum haemorrhage		✕
Neonatal outcomes:
Newborn’s weight			✕
Admission in neonatal care unit (yes/no)			✕
Apgar Score			✕
Fetal growth retardation			✕
Any morbidity of the newborn that results in hospitalisation in the first 3 months of life					✕
Emollient usage	Total volume, brand, frequency				✕	✕	✕
Bathing practice	Frequency, duration of bathing, bath temperature, cleanser usage, soap usage				✕	✕	✕
Patient disease knowledge and attitude changes	Questionnaire currently under validation	✕		✕	✕	✕	✕

AD, atopic dermatitis; EASI, Eczema Area and Severity Index; IDQOL, Infantile Dermatitis Quality of Life; IGA, Investigator Global Assessment; OB, obstetrics; PAEPAD, Preventive Antenatal Educational Program on Allergic Diseases; SCORAD, SCORing of Atopic Dermatitis.